首页> 外文OA文献 >Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

【2h】

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

机译：每周Paclitaxel Plus Ramucirumab与每周Nab-Paclitaxel加上Ramucirumab与腹膜传播难以进行一线治疗 - P-SELECT试验（WJOG10617G）-A由西日本肿瘤学组进行随机化第二次审判

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Kenro Hirata; Yasuo Hamamoto; Masahiko Ando; Chiyo K. Imamura; Kenichi Yoshimura; Kentaro Yamazaki; Shuichi Hironaka; Kei Muro;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial [J] . Maria Di Bartolomeo, Monica Niger, Federica Morano, BMC Cancer . 2019,第1期

机译：评估RAMUCIRUMAB PLUS PACLITAXEL作为开关维修与先进的HER-2阴性胃或胃食管结癌患者的一线化疗延续：ARMANI期III试验
2. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial [J] . SocinskiM.A., BondarenkoI., KarasevaN.A., Journal of Clinical Oncology . 2012,第17期

机译：纳博-紫杉醇联合卡铂与溶剂型紫杉醇联合卡铂作为晚期非小细胞肺癌患者的一线治疗：III期试验的最终结果
3. Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: A multicenter open random phase II trial [J] . DengT., XuN., XiongJ.-P., Journal of chemotherapy . 2013,第1期

机译：每周一次紫杉醇加S-1与紫杉醇加5-氟尿嘧啶/叶酸钙作为晚期胃癌一线治疗的安全性分析：一项多中心开放式随机II期试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group [O] . Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, 2020

机译：每周紫杉醇联合雷莫昔单抗与每周纳布紫杉醇联合雷莫西单抗治疗无法切除的晚期或复发性胃癌但一线治疗难治性腹膜扩散-P-SELECT试验（WJOG10617G）-西日本肿瘤学小组的一项随机II期试验
6. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. [O] . Gasparini G, Gion M, Mariani L, 2006

机译：每周单独紫杉醇与曲妥珠单抗加每周紫杉醇作为Her-2阳性晚期乳腺癌患者的一线治疗的随机II期试验。

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

著录项

相似文献

相关主题

期刊订阅